Based on the provided forecast data, the year-on-year variations in antihypertensive medicine sales in Germany are as follows:
- 2024 to 2025: 1.06% increase
- 2025 to 2026: 1.05% increase
- 2026 to 2027: 1.02% increase
- 2027 to 2028: 1.01% increase
The Compound Annual Growth Rate (CAGR) over the last five years is approximately 1.035%.
As the German population ages and the prevalence of hypertension continues to rise, the demand for antihypertensive medications is expected to see steady growth. Innovations in treatment, including the development of new drug classes and personalized medicine, could further drive market expansion. Monitoring regulatory changes and healthcare policies will also be critical in predicting future market dynamics.
